about
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individualsSafety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapyComparison of auditory brainstem response in HIV-1 exposed and unexposed newborns and correlation with the maternal viral load and CD4+ cell countsReviving protease inhibitors: new data and more options.Enhancement of health research capacity in Nigeria through north-south and in-country partnerships.Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection.ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients.Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in NigeriaMycobacterium tuberculosis and Mycobacterium africanum in stools from children attending an immunization clinic in Ibadan, Nigeria.Evaluation of gene xpert for routine diagnosis of HIV-associated tuberculosis in Nigeria: A prospective cohort study.Outcome of HIV-associated lymphoma in a resource-limited setting of Jos, Nigeria.Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled StudyA family history study of male sexual orientation using three independent samples.Skin test reactivity and cellular immune responses to Mycobacterium avium sensitin in AIDS patients at risk for disseminated M. avium infectionInterplay of reverse transcriptase inhibitor therapy and gag p6 diversity in HIV type 1 subtype G and CRF02_AGInterferon-alpha administration enhances CD8+ T cell activation in HIV infectionSafety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial.A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learnedRisk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy.High-risk human papilloma virus and cervical abnormalities in HIV-infected women with normal cervical cytology.Switch studies: a review.Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362.Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.The pavia consensus statement.Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings.Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults.Evaluating therapeutic vaccines in patients infected with HIV.Host gene expression changes correlating with anti-HIV-1 effects in human subjects after treatment with peginterferon Alfa-2a.Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settingsA prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness.
P50
Q24802369-C7ECDC25-93CC-495A-B45E-AFF825940037Q28279534-AEAC3CF8-05D5-4A4F-931F-A7FFD9BA1253Q28374983-8CFF3F1E-D7CE-4711-96C5-6F0F4A236F6BQ30395110-9195D472-AA1D-4A7A-825F-B2BF1CB08539Q30402510-5C7EB3D5-0960-4A8D-A69F-865ED655D103Q30821505-45667286-3AB0-4252-8EA0-CD30F1EEE639Q30833646-FA0443A9-166D-47A0-81AD-6D07F57912BBQ31934105-009EB3BB-A688-4EC9-B868-35C3C92CDC96Q31977860-00EA7FC2-B9B8-4813-92EA-AC13E2C5C952Q33494024-34C4336D-763D-4F6D-984D-CB58B008D500Q33539266-E1264ED5-4838-4965-B01D-086A7289EEE4Q33625367-0B6A25E9-05A0-49F5-AC49-852E6EC715E7Q33725875-8478C5D8-A585-4045-BA52-31A08048C3C0Q33742861-76027F11-4EEC-42A1-9F69-31B27D6A122FQ33767818-C75C7393-3F3C-4537-A0ED-20ED74090F8CQ33843685-283E2697-743B-40AA-8CEB-068C52DFD340Q33868009-51FD2119-1972-4905-9E98-2A83807E1D47Q33999820-15E98B79-8CF0-450C-A48C-25E23360FD7CQ34083261-7B7DC797-CD34-4DD3-AB15-7D026CBF24B7Q34145979-71F6FE33-2CC6-4E0B-A8AF-F72FEDED37F9Q34158350-42FCB19A-1412-4987-8742-757CA5321758Q34184881-4FF2D6CE-9CA9-46B7-8325-9FD1EC457944Q34191241-D05EC91E-F61A-4C97-8652-4601D0A1DD3CQ34374655-BF64FC04-8C49-48FE-9E5B-75B3F70D8B2FQ34416516-26F74701-8956-456E-B18C-0782013B77ACQ34503722-F61DDF16-2753-4298-9CF5-B136CBF304F6Q34636824-8A7CC135-5274-4F33-B012-CE0ED95A77B4Q34984627-1FEDFA54-AFAD-47E7-9D00-4E2DEC41B35FQ35079510-FEC82A9D-FA91-40FE-B489-49083C52B317Q35180779-96DD6AEB-239B-459E-A019-FDB521E6C430Q35214141-B218CE44-286F-49E7-A45D-0B6CDB137D5CQ35233168-0B2CCDBF-7144-456E-ABE7-FC69509DD2B8Q35636520-4375A926-FD08-4B41-951E-ABE0B6AC1001Q35759403-01AEAF54-D6A8-458F-91B7-E2863060FA60Q35829744-83997195-19AD-43DF-92F6-822C19A81B6AQ35851820-429E01D0-5BE5-4F02-92E9-181D9C87C0AEQ35883429-289ABF52-A1C4-46BD-8CE7-C31212CB0937Q35974422-B3B4F752-F452-43AD-8FBD-929071C957E1Q35993860-F8AE0B7F-FFF2-4D44-8A39-5BBECCE90055Q36063551-D55D9490-02CD-41D1-9DCC-C92944794EC7
P50
description
Amerikaans onderzoeker
@nl
professor of medicine
@en
name
Robert L. Murphy
@en
Robert L. Murphy
@es
Robert Murphy
@ast
Robert Murphy
@nl
Robert Murphy
@sl
type
label
Robert L. Murphy
@en
Robert L. Murphy
@es
Robert Murphy
@ast
Robert Murphy
@nl
Robert Murphy
@sl
altLabel
R L Murphy
@en
R. L. Murphy
@en
Robert L Murphy
@en
Robert Leo Murphy
@en
Robert Murphy
@en
prefLabel
Robert L. Murphy
@en
Robert L. Murphy
@es
Robert Murphy
@ast
Robert Murphy
@nl
Robert Murphy
@sl
P4012
P973
P214
P244
P6366
P106
P1153
35373811100
P1412
P1559
Robert Leo Murphy
@en